Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial

Published:2018-08 Issue: Volume:85 Page:116-125
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Basolo Alessio,Burkholder Joshua,Osgood Kristy,Graham Alexis,Bundrick Sarah,Frankl Joseph,Piaggi Paolo,Thearle Marie S.,Krakoff Jonathan

Funder

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference44 articles.

1. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials;Monami;Eur J Endocrinol,2009

2. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials;Buse;Clin Ther,2007

3. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes;DeFronzo;Diabetes Care,2005

4. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes;Nelson;Diabetes Technol Ther,2007

5. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes;Dushay;Diabetes Care,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study;Scientific Reports;2024-05-18

2. Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity;Diabetes, Obesity and Metabolism;2024-04

3. Therapeutic Repurposing of Antidiabetic Drugs in Diabetes-associated Comorbidities;Current Drug Therapy;2024-03

4. Chemogenetic inhibition of the lateral hypothalamus in rats: A simple but robust tool with high translational relevance to facilitate the development of central nervous system-targeted gene therapies;2023-12-14

5. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials;The American Journal of Clinical Nutrition;2023-09